Sanofi-aventis Us Drug Patent Portfolio
Sanofi-aventis Us owns 3 orange book drugs protected by 39 US patents Given below is the list of Sanofi-aventis Us's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9950039 | Insulin glargine/lixisenatide fixed ratio formulation | 10 Dec, 2035 | Active |
| US10201663 | Assembly for a drug delivery device | 10 Mar, 2034 | Active |
| US9717852 | Cartridge holder and pen-type injector | 08 Apr, 2033 | Active |
| US9408893 | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients | 27 Aug, 2032 | Active |
| US9821032 | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin | 09 May, 2032 | Active |
| US9072836 | Drive mechanism for a drug delivery device and drug delivery device | 15 Mar, 2032 | Active |
| US9440029 | Drive mechanism for a drug delivery device and drug delivery device | 30 Jan, 2032 | Active |
| US9511193 | Assembly and indicator for a drug delivery device | 19 Jan, 2032 | Active |
| US9084853 | Drive mechanism for a drug delivery device and drug delivery device | 05 Oct, 2031 | Active |
| US8882721 | Drive assembly suitable for use in a drug delivery device and drug delivery device | 28 Jun, 2031 | Active |
| US8475414 | Medication delivery device and method for operating a medication delivery device | 28 Dec, 2030 | Active |
| US9308329 | Medication delivery device and method for operating a medication delivery device | 28 Dec, 2030 | Active |
| US10028910 | Pharmaceutical composition comprising a GLP-1-agonist and methionine | 11 Nov, 2030 | Active |
| US9707176 | Pharmaceutical composition comprising a GLP-1 agonist and methionine | 11 Nov, 2030 | Active |
| US10029011 | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine | 11 Nov, 2030 | Active |
| US9981013 | Use of AVE0010 for the treatment of diabetes mellitus type 2 | 30 Aug, 2030 | Active |
| US8915888 | Dosing and drive mechanism for drug delivery device | 08 Jun, 2030 | Active |
| US10117909 | Combination of an insulin and a GLP-1 agonist | 09 Oct, 2029 | Active |
| US9526764 | Combination of an insulin and a GLP-1-agonist | 09 Oct, 2029 | Active |
| US9855388 | Dosing and drive mechanism for drug delivery device | 24 Apr, 2029 | Active |
| US7918833 | Pen-type injector | 23 Sep, 2027 | Active |
| US8679069 | Pen-type injector | 12 Apr, 2025 | Active |
| US8512297 | Pen-type injector | 15 Sep, 2024 | Expired |
| US9561331 | Drive mechanisms suitable for use in drug delivery devices | 28 Aug, 2024 | Expired |
| US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices | 19 Aug, 2024 | Expired |
| US9533105 | Drive mechanisms suitable for use in drug delivery devices | 17 Aug, 2024 | Expired |
| US9604009 | Drive mechanisms suitable for use in drug delivery devices | 16 Aug, 2024 | Expired |
| US8992486 | Pen-type injector | 05 Jun, 2024 | Expired |
| US9011391 | Pen-type injector | 26 Mar, 2024 | Expired |
| US8556864 | Drive mechanisms suitable for use in drug delivery devices | 03 Mar, 2024 | Expired |
| US8603044 | Pen-type injector | 02 Mar, 2024 | Expired |
| US9233211 | Relating to a pen-type injector | 02 Mar, 2024 | Expired |
| US9408979 | Pen-type injector | 02 Mar, 2024 | Expired |
| US9526844 | Pen-type injector | 02 Mar, 2024 | Expired |
| US9604008 | Drive mechanisms suitable for use in drug delivery devices | 02 Mar, 2024 | Expired |
| US9610409 | Drive mechanisms suitable for use in drug delivery devices | 02 Mar, 2024 | Expired |
| US9775954 | Pen-type injector | 02 Mar, 2024 | Expired |
| US9827379 | Drive mechanisms suitable for use in drug delivery devices | 02 Mar, 2024 | Expired |
| USRE45313 | Exendin variant peptides | 12 Jul, 2020 | Expired |
Latest Legal Activities on Sanofi-aventis Us's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sanofi-aventis Us.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jun, 2024 | US9533105 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Jun, 2024 | US9526764 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 May, 2024 | US9511193 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Feb, 2024 | US9440029 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jan, 2024 | US9408979 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jan, 2024 | US9408893 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Sep, 2023 | US9308329 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Jun, 2023 | US9233211 (Litigated) |
| Post Issue Communication - Certificate of Correction | 27 Jan, 2023 | US10201663 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Jan, 2023 | US9084853 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Dec, 2022 | US9072836 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Oct, 2022 | US9011391 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Sep, 2022 | US7918833 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Sep, 2022 | US8992486 (Litigated) |
| Review Certificate Mailed | 30 Aug, 2022 | US9526844 |
Sanofi-aventis Us's Drug Patent Litigations
Sanofi-aventis Us's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 10, 2018, against patent number US8992486. The petitioner Mylan Pharmaceuticals Inc et al., challenged the validity of this patent, with Sanofi-Aventis Deutschland GmbH et al. as the respondent. Click below to track the latest information on how companies are challenging Sanofi-aventis Us's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8679069 | May, 2019 |
FWD Entered
(11 Aug, 2020)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US8603044 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8992486 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8992486 | October, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US9526844 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc |
| US9526844 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US9604008 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8679069 | September, 2018 |
FWD Entered
(02 Apr, 2020)
| Sanofi-Aventis Deutshland GmbH | Mylan Pharmaceuticals Inc. |
| US9526844 | May, 2019 |
Terminated-Other
(20 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US9526844 | May, 2019 |
Terminated-Other
(19 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US8603044 | May, 2019 |
Terminated-Other
(15 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US8992486 | May, 2019 |
Terminated-Other
(15 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US9604008 | May, 2019 |
Terminated-Other
(15 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US9526844 | September, 2018 |
Terminated-Denied
(03 Apr, 2019)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8992486 | September, 2018 |
Terminated
(19 Dec, 2018)
| Sanofi-Aventis Deutschland GmbH et al. | Mylan Pharmaceuticals Inc et al. |
Sanofi-aventis Us's Family Patents
Sanofi-aventis Us Drug List
Given below is the complete list of Sanofi-aventis Us's drugs and the patents protecting them.
1. Adlyxin
Adlyxin is protected by 16 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10201663 | Assembly for a drug delivery device |
10 Mar, 2034
(9 years from now)
| Active |
| US9408893 | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
27 Aug, 2032
(7 years from now)
| Active |
| US9821032 | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
09 May, 2032
(7 years from now)
| Active |
| US9072836 | Drive mechanism for a drug delivery device and drug delivery device |
15 Mar, 2032
(7 years from now)
| Active |
| US9440029 | Drive mechanism for a drug delivery device and drug delivery device |
30 Jan, 2032
(7 years from now)
| Active |
| US9511193 | Assembly and indicator for a drug delivery device |
19 Jan, 2032
(7 years from now)
| Active |
| US9084853 | Drive mechanism for a drug delivery device and drug delivery device |
05 Oct, 2031
(6 years from now)
| Active |
| US8882721 | Drive assembly suitable for use in a drug delivery device and drug delivery device |
28 Jun, 2031
(6 years from now)
| Active |
| US8475414 | Medication delivery device and method for operating a medication delivery device |
28 Dec, 2030
(6 years from now)
| Active |
| US9308329 | Medication delivery device and method for operating a medication delivery device |
28 Dec, 2030
(6 years from now)
| Active |
| US10028910 | Pharmaceutical composition comprising a GLP-1-agonist and methionine |
11 Nov, 2030
(5 years from now)
| Active |
| US9707176 | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
11 Nov, 2030
(5 years from now)
| Active |
| US9981013 | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
30 Aug, 2030
(5 years from now)
| Active |
| US8915888 | Dosing and drive mechanism for drug delivery device |
08 Jun, 2030
(5 years from now)
| Active |
| US9855388 | Dosing and drive mechanism for drug delivery device |
24 Apr, 2029
(4 years from now)
| Active |
| USRE45313 | Exendin variant peptides |
12 Jul, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adlyxin's drug page
2. Admelog Solostar
Admelog Solostar is protected by 19 patents, out of which 16 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9717852 | Cartridge holder and pen-type injector |
08 Apr, 2033
(8 years from now)
| Active |
| US7918833 | Pen-type injector |
23 Sep, 2027
(2 years from now)
| Active |
| US8679069 | Pen-type injector |
12 Apr, 2025
(3 months from now)
| Active |
| US8512297 | Pen-type injector |
15 Sep, 2024
(3 months ago)
| Expired |
| US9561331 | Drive mechanisms suitable for use in drug delivery devices |
28 Aug, 2024
(3 months ago)
| Expired |
| US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
19 Aug, 2024
(3 months ago)
| Expired |
| US9533105 | Drive mechanisms suitable for use in drug delivery devices |
17 Aug, 2024
(4 months ago)
| Expired |
| US9604009 | Drive mechanisms suitable for use in drug delivery devices |
16 Aug, 2024
(4 months ago)
| Expired |
| US8992486 | Pen-type injector |
05 Jun, 2024
(6 months ago)
| Expired |
| US9011391 | Pen-type injector |
26 Mar, 2024
(8 months ago)
| Expired |
| US9827379 | Drive mechanisms suitable for use in drug delivery devices |
04 Mar, 2024
(9 months ago)
| Expired |
| US8556864 | Drive mechanisms suitable for use in drug delivery devices |
03 Mar, 2024
(9 months ago)
| Expired |
| US8603044 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
| US9233211 | Relating to a pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
| US9408979 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
| US9526844 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
| US9604008 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(9 months ago)
| Expired |
| US9610409 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(9 months ago)
| Expired |
| US9775954 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Admelog Solostar's drug page
3. Soliqua 100/33
Soliqua 100/33 is protected by 26 patents, out of which 17 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9950039 | Insulin glargine/lixisenatide fixed ratio formulation |
10 Dec, 2035
(10 years from now)
| Active |
| US9717852 | Cartridge holder and pen-type injector |
08 Apr, 2033
(8 years from now)
| Active |
| US9821032 | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
09 May, 2032
(7 years from now)
| Active |
| US10029011 | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
11 Nov, 2030
(5 years from now)
| Active |
| US9707176 | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
11 Nov, 2030
(5 years from now)
| Active |
| US10117909 | Combination of an insulin and a GLP-1 agonist |
09 Oct, 2029
(4 years from now)
| Active |
| US9526764 | Combination of an insulin and a GLP-1-agonist |
09 Oct, 2029
(4 years from now)
| Active |
| US7918833 | Pen-type injector |
23 Sep, 2027
(2 years from now)
| Active |
| US8679069 | Pen-type injector |
12 Apr, 2025
(3 months from now)
| Active |
| US8512297 | Pen-type injector |
15 Sep, 2024
(3 months ago)
| Expired |
| US9561331 | Drive mechanisms suitable for use in drug delivery devices |
28 Aug, 2024
(3 months ago)
| Expired |
| US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
19 Aug, 2024
(3 months ago)
| Expired |
| US9533105 | Drive mechanisms suitable for use in drug delivery devices |
17 Aug, 2024
(4 months ago)
| Expired |
| US9604009 | Drive mechanisms suitable for use in drug delivery devices |
16 Aug, 2024
(4 months ago)
| Expired |
| US8992486 | Pen-type injector |
05 Jun, 2024
(6 months ago)
| Expired |
| US9011391 | Pen-type injector |
26 Mar, 2024
(8 months ago)
| Expired |
| US8556864 | Drive mechanisms suitable for use in drug delivery devices |
03 Mar, 2024
(9 months ago)
| Expired |
| US8603044 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
| US9233211 | Relating to a pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
| US9408979 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
| US9526844 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
| US9604008 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(9 months ago)
| Expired |
| US9610409 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(9 months ago)
| Expired |
| US9775954 | Pen-type injector |
02 Mar, 2024
(9 months ago)
| Expired |
| US9827379 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(9 months ago)
| Expired |
| USRE45313 | Exendin variant peptides |
12 Jul, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Soliqua 100/33's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List